Welcome to our dedicated page for Lixte Biotechnology Holdings news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Holdings stock.
Lixte Biotechnology Holdings, Inc. (symbol: LIXT) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer. The company has made significant strides in identifying molecular signaling pathways that are altered in various disease states. By designing compounds that can safely target these pathways in animal models, Lixte aims to enhance the effectiveness of existing cancer treatments.
The company's drug portfolio includes inhibitors of protein phosphatases and protein deacetylases. These inhibitors are crucial for cell division, DNA damage repair, and the regulation of gene expression and protein degradation. The phosphatase inhibitors, in particular, have shown potential in increasing the efficacy of cytotoxic anti-cancer drugs and radiation therapy. This makes them potentially useful for the treatment of a wide range of cancers when used in combination with standard chemotherapy regimens and emerging targeted therapies.
Lixte's lead compound, LB-100, is currently in Phase I trials and has the potential to be a first-in-class treatment. LB-100 has shown promising clinical anti-cancer activity with minimal toxicity. This compound is being developed as a protein phosphatase 2A inhibitor and has potential applications in combination with cytotoxic agents, x-rays, immune checkpoint blockers, and other cancer therapies.
In addition to its primary focus on protein phosphatase inhibitors, Lixte is exploring the therapeutic potential of protein deacetylase inhibitors. These inhibitors are involved in regulating gene expression and protein degradation pathways, offering another avenue for cancer treatment development.
Lixte Biotechnology Holdings, Inc. continues to make significant advancements in cancer research, aiming to provide more effective treatment options for patients worldwide. The company's ongoing projects, strategic partnerships, and innovative drug portfolio position it as a key player in the biopharmaceutical industry.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) has received a Notice of Allowance from the USPTO for a patent application covering the combination of its LB-100 compound with various cancer immunotherapies. This patent strengthens LIXTE's intellectual property portfolio and highlights its commitment to innovative cancer research. The company is currently conducting clinical trials at the Netherlands Cancer Institute and MD Anderson Cancer Center, testing LB-100 in combination with immunotherapies for metastatic colon cancer and ovarian clear cell carcinoma. LIXTE recently signed an exclusive patent license agreement with NINDS and NCI, opening up opportunities for developing novel combination therapies in cancer treatment.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) has announced the dosing of the first patient in a new clinical trial for treating unresponsive metastatic colorectal cancer. The trial is a collaboration with the Netherlands Cancer Institute (NKI) and is supported by Roche. LIXTE is providing its lead compound, LB-100, while Roche is supplying atezolizumab (Tecentriq®), a PDL1 inhibitor. The trial aims to make immunotherapy an effective treatment option for approximately 85% of colorectal cancer patients who have not responded to traditional protocols. This marks the second recent clinical trial combining LB-100 with immunotherapy funded by a major pharmaceutical company, following an earlier trial with GSK for clear cell ovarian cancer treatment.
LIXTE Biotechnology Holdings, Inc. (LIXT) has announced several significant developments:
1. A new collaboration with The Netherlands Cancer Institute, supported by Roche, for a clinical trial in metastatic colorectal cancer using LB-100 and atezolizumab.
2. Appointment of Dr. Jan Schellens as Chief Medical Officer, bringing extensive oncology and drug development experience.
3. Publication of preclinical data in EMBO Reports showing LB-100's potential to enhance immunotherapy benefits.
4. Ongoing clinical trials, including a GSK-funded study of LB-100 with dostarlimab-gxly in ovarian clear cell cancer and a soft tissue sarcomas trial with expected data in early 2025.
5. Upcoming presentations at two investor conferences in August and September 2024.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) announced its participation in two upcoming investor conferences. The company will present at the Investor Summit Summer 2024 Virtual Conference on August 20, 2024, at 2 p.m. EDT, and the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024.
CEO Bas van der Baan will provide an overview of LIXTE's clinical trials with LB-100, their proprietary compound designed to enhance chemotherapy and immunotherapy treatments for cancer. The company is currently conducting proof-of-concept clinical trials for colorectal, ovarian, and sarcoma cancers, including trials funded by GSK and Roche.
Investors can access the presentations through LIXTE's investor relations website and the H.C. Wainwright conference registration page.
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company specializing in cancer drug development, is set to participate in the Q3 Investor Summit on August 20th, 2024. The event, focused on 50 micro-cap companies with catalysts or strong market performance, will feature Lixte's presentation at 2:00 pm ET.
Investors can access the presentation via a live webcast. Throughout the day, Lixte will also be available for one-on-one meetings with interested parties. This summit provides an opportunity for qualified investors to engage with promising micro-cap companies, offering live Q&A sessions and in-depth discussions.
LIXTE Biotechnology Holdings announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial targeting immune therapy unresponsive (MSI Low) metastatic colon cancer. The trial, listed as NCT06012734, will investigate the efficacy of LIXTE's lead compound, LB-100, in combination with Roche's PD-L1 inhibitor, atezolizumab (Tecentriq®). Approximately 85% of colon cancers are MSI Low and non-responsive to immunotherapy. The aim is to enhance immunotherapy efficacy for these patients. The collaboration highlights the scientific potential of LB-100, which has shown promise in pre-clinical data and previous trials. This study is the second recent collaboration with a major pharmaceutical company, following a GSK-supported trial for clear cell ovarian cancer.
LIXTE Biotechnology Holdings has announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) for a new clinical trial targeting MSI Low metastatic colon cancer. The trial, registered as NCT06012734, will test LIXTE's lead compound LB-100 in combination with Roche's PD-L1 inhibitor, atezolizumab. NKI's Dr. Neeltje Steeghs will lead the trial, aiming to improve immunotherapy efficacy for the 85% of colon cancers unresponsive to current treatments. This collaboration follows another recent trial funded by GSK for clear cell ovarian cancer, highlighting the pharmaceutical industry's support for LB-100's potential. This trial could significantly impact colon cancer treatment by making immunotherapy viable for a larger patient group.
LIXTE Biotechnology Holdings announced new pre-clinical data published in EMBO Reports showing that its lead compound, LB-100, can potentially enhance immunotherapy effectiveness in colon cancer. LB-100 has been found to disrupt mRNA splicing in cancer cells, creating neo-antigens that boost immune system recognition. This mechanism could help turn immunologically 'cold' tumors 'hot,' making them more susceptible to immunotherapy. The study, conducted by researchers at the Netherlands Cancer Institute, adds to existing data supporting LB-100's role in sensitizing cancer cells to immune checkpoint blockade. This discovery is expected to expand clinical trial efforts, particularly in lung and ovarian cancer, and could significantly increase the number of colon cancer patients responding to immunotherapy.
LIXTE Biotechnology Holdings has appointed Dr. Jan Schellens as the new Chief Medical Officer, effective August 1, 2024, succeeding Dr. James S. Miser.
Dr. Schellens brings over 25 years of clinical experience in oncology and pharmacology, including leadership roles at prominent institutions like the Netherlands Cancer Institute.
He is expected to significantly contribute to LIXTE's development of LB-100, which aims to enhance chemotherapy and immunotherapy treatments. Dr. Schellens has co-authored over 900 scientific publications and has had significant roles on various medical boards and advisory committees.
LIXTE CEO Bas van der Baan expressed confidence in Dr. Schellens' ability to drive the company's growth and development in cancer therapeutics.
LIXTE Biotechnology provided an update on their recent activities. Key highlights include promising pre-clinical data on their compound LB-100 in a new field of cancer biology called 'activation lethality.' The findings suggest that LB-100 can force cancer cells to lose their cancer-causing properties, potentially opening new treatment strategies alongside ongoing clinical trials in lung, ovarian, and sarcoma cancers. The data was presented by Dr. René Bernards at a major cancer research conference and published in the journal Cancer Discovery.
CEO Bas van der Baan presented at the MedInvest Biotech and Pharma Investor Conference. LIXTE co-sponsored an international workshop at Harvard’s Dana Farber Cancer Institute, discussing innovative cancer therapy approaches. Clinical trials for LB-100 are underway at various prestigious institutions, including the University of Texas MD Anderson Cancer, City of Hope Cancer Center, Sarah Cannon Research Institute, and the Spanish Sarcoma Group. In February 2024, LIXTE signed an exclusive patent license agreement with the NIH. The company's latest financial data is available in their quarterly report filed with the SEC.
FAQ
What is the current stock price of Lixte Biotechnology Holdings (LIXT)?
What is the market cap of Lixte Biotechnology Holdings (LIXT)?
What is Lixte Biotechnology Holdings, Inc.?
What are the main products of Lixte?
What is LB-100?
How do Lixte's phosphatase inhibitors work?
What diseases does Lixte target?
What stage is Lixte's drug development in?
Are Lixte's treatments safe?
What partnerships has Lixte formed?
How can investors get in touch with Lixte?
Where can more information about Lixte be found?
